Welcome to our dedicated page for LifeStance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group (LFST) reported higher Q3 2025 results. Total revenue reached $363.8 million, up from $312.7 million a year ago. Income from operations was $7.4 million versus $0.05 million, and net income was $1.1 million compared with a prior-year net loss. For the first nine months, revenue was $1.04 billion and net loss narrowed to $2.0 million.
Cash and cash equivalents were $203.9 million, and net cash provided by operating activities rose to $88.6 million for the nine-month period. Long-term debt, net, was $269.4 million. Q3 Center Margin was $116.6 million and Adjusted EBITDA was $40.2 million. The company remained in compliance with debt covenants.
Commercial payors represented 90% of Q3 revenue, with government at 5% and self-pay at 4%. The interest rate swap matured on September 30, 2025. As of October 29, 2025, 389,000,281 common shares were outstanding.
LifeStance Health Group, Inc. (LFST) furnished quarterly materials. The company announced it furnished a press release covering results for the third quarter ended September 30, 2025 under Item 2.02, and a supplemental investor slide presentation under Item 7.01.
Both items are furnished, not filed, and are not incorporated by reference into other SEC filings unless expressly referenced. Exhibits include 99.1 (press release dated November 6, 2025) and 99.2 (supplemental slides), along with the Inline XBRL cover page file.
LifeStance Health Group (LFST) reported an insider equity award. A director acquired 74,766 shares of common stock on 08/20/2025 at $0.00, as shown on a Form 4.
The filing states these are restricted stock units (RSUs), with each RSU representing a right to receive one share of common stock. Following the reported transaction, the director beneficially owned 74,766 shares, held directly.
LifeStance Health Group (LFST) filed a Form 3 reporting the initial beneficial ownership of a director as of 08/20/2025. The filing states that no securities are beneficially owned. It was submitted by one reporting person and includes an Exhibit 24 Power of Attorney. This is an administrative disclosure required under Section 16 and does not reflect a transaction.
LifeStance Health Group insider report: Ann Varanakis, Chief People Officer and director, had restricted stock units vest on 08/26/2025. The issuer withheld 5,233 shares to satisfy tax withholding at $5.39 per share; this withholding is a net settlement and not an open-market sale. After the transaction, Ms. Varanakis beneficially owns 369,335 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and indicates the filing was made by one reporting person.
LifeStance Health Group reported a change in its board of directors. On August 19, 2025, William Miller resigned from the board and all its committees, effective immediately, and the company states his resignation was not due to any disagreement with the company. On August 20, 2025, the board appointed Sarah Personette as a new director.
In connection with her appointment, and under the company’s 2021 Equity Incentive Plan, Ms. Personette received an initial grant of 74,766 restricted stock units. These RSUs will vest based on time and performance conditions, subject to her continued service on the board.
Silversmith Partners reported an insider sale of common stock in LifeStance Health Group, Inc. (LFST). On 08/18/2025 the Silversmith Entities disposed of 3,592,357 shares at a price of $5.07 per share. After that transaction the reporting parties beneficially owned 14,324,197 shares on an indirect basis. The filing breaks down the indirect holdings: Silversmith Capital Partners I-A, L.P. holds 9,855,844 shares, Silversmith Capital Partners I-B, L.P. holds 3,565,133 shares, and Silversmith Capital Partners I-C, L.P. holds 903,220 shares. The report includes standard disclaimers that each reporting person disclaims beneficial ownership except to the extent of pecuniary interest and notes a stockholders agreement that may create a Section 13(d) "group" with other large holders. The form is signed by Jeffrey R. Crisan on 08/20/2025.
Darren M. Black, a director and 10% owner affiliate, reported a sale of 8,407,643 shares of LifeStance Health Group, Inc. (LFST) on 08/18/2025 at a price of $5.07 per share. The shares sold were held across multiple Summit-related funds as detailed in the filing. After the transaction, the reporting parties continue to beneficially own a total of 33,524,715 shares held indirectly through Summit entities. The filing clarifies the ownership chain: Mr. Black is a Managing Director and Member of Summit Master Company, LLC, which through a series of partnerships and management relationships holds voting and dispositive authority over the reported shares.
Insider sale by Summit Partners entities: On 08/18/2025 multiple Summit-related entities reported an aggregate sale of 8,407,643 shares of LifeStance Health Group, Inc. (LFST) at a price of $5.07 per share. After the reported transactions, the entities collectively beneficially own 33,524,715 shares held across five Summit funds and entities. The filings identify Summit Partners, L.P. as the manager with voting and dispositive authority exercised by a four-person investment committee. The report was signed and filed on 08/20/2025 by authorized representatives of the Summit entities.
LifeStance Health Group, Inc. (LFST) filed a Form 144 notifying a proposed sale of 894,098 shares of Common Stock through Morgan Stanley & Co. LLC, with an aggregate market value of $4,837,070.18. The filing lists the approximate date of sale as 08/18/2025 and the securities exchange as NASDAQ.
The shares were acquired pre-IPO on 06/10/2021 from the issuer, with 5,130,460 shares originally acquired on that date. The filer reports no securities sold in the past three months and includes the required certification that no undisclosed material adverse information is known.